NIH RECOMBINANT DNA ADVISORY COMMITTEE WILL REVIEW SIX PROTOCOLS
NIH RECOMBINANT DNA ADVISORY COMMITTEE WILL REVIEW SIX PROTOCOLS at its Dec. 1-2 meeting. Additionally, the RAC will hear a report by RAC Chairman LeRoy Walters on "minor modifications" to protocols already approved by NIH; a report from the working group on data management pertaining to actions to be taken when principal investigators of NIH-approved gene therapy protocols fail to provide reports to the Office of Recombinant DNA Activities; and a review of Appendix B, the updated list of the Classification of Microorganisms on Basis of Hazard, which by then will have been reviewed by experts from the Centers for Disease Control & Prevention and the American Society for Microbiology. At its Sept. 12-13 meeting, the RAC decided to await letters of concurrence from CDC and ASM before adopting Appendix B.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth